09:15 AM EDT, 03/13/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Wednesday that interim analysis from a phase 2 trial of mezagitamab, which is intended for persistent or chronic primary immune thrombocytopenia, showed higher platelet response rates compared with placebo across all three dose cohorts.

The company said the trial tested three different doses of subcutaneous mezagitamab against placebo, administered once weekly for eight weeks. An interim analysis showed the antibody was "generally safe and well tolerated" with the greatest response observed at the highest mezagitamab dose, Takeda added.

Takeda said it plans to initiate a global phase 3 trial for mezagitamab in fiscal 2024.

Primary immune thrombocytopenia is a rare autoimmune disease characterized by accelerated destruction of platelets.

Price: 14.38, Change: +0.01, Percent Change: +0.04